

# James D Chambers

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/333229/publications.pdf>

Version: 2024-02-01

54  
papers

947  
citations

394421

19  
h-index

477307

29  
g-index

55  
all docs

55  
docs citations

55  
times ranked

1042  
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk-Sharing Arrangements That Link Payment For Drugs To Health Outcomes Are Proving Hard To Implement. Health Affairs, 2011, 30, 2329-2337.	5.2	90
2	Listening to Provenge â€” What a Costly Cancer Treatment Says about Future Medicare Policy. New England Journal of Medicine, 2011, 364, 1687-1689.	27.0	58
3	Does Medicare Have an Implicit Cost-Effectiveness Threshold?. Medical Decision Making, 2010, 30, E14-E27.	2.4	52
4	The influence of time horizon on results of cost-effectiveness analyses. Expert Review of Pharmacoeconomics and Outcomes Research, 2017, 17, 615-623.	1.4	51
5	Medicare's Enduring Struggle to Define â€œReasonable and Necessaryâ€-Care. New England Journal of Medicine, 2012, 367, 1775-1777.	27.0	49
6	Specialty Drug Coverage Varies Across Commercial Health Plans In The US. Health Affairs, 2018, 37, 1041-1047.	5.2	45
7	Hemophilia Burden of Disease: A Systematic Review of the Cost-Utility Literature for Hemophilia. Journal of Managed Care & Specialty Pharmacy, 2018, 24, 632-642.	0.9	35
8	Private Payers Disagree With Medicare Over Medical Device Coverage About Half The Time. Health Affairs, 2015, 34, 1376-1382.	5.2	33
9	Factors Predicting Medicare National Coverage. Medical Care, 2012, 50, 249-256.	2.4	29
10	A Review of Empirical Analyses of Disinvestment Initiatives. Value in Health, 2017, 20, 909-918.	0.3	29
11	Orphan Drugs Offer Larger Health Gains but Less Favorable Cost-effectiveness than Non-orphan Drugs. Journal of General Internal Medicine, 2020, 35, 2629-2636.	2.6	29
12	Therapies For Advanced Cancers Pose A Special Challenge For Health Technology Assessment Organizations In Many Countries. Health Affairs, 2012, 31, 700-708.	5.2	28
13	What can we learn from the U.S. expanded end-stage renal disease bundle?. Health Policy, 2013, 110, 164-171.	3.0	28
14	Medicare Is Scrutinizing Evidence More Tightly For National Coverage Determinations. Health Affairs, 2015, 34, 253-260.	5.2	28
15	An Assessment of the Methodological Quality of Published Network Meta-Analyses: A Systematic Review. PLoS ONE, 2015, 10, e0121715.	2.5	28
16	Medicare Covers The Majority Of FDA-Approved Devices And Part B Drugs, But Restrictions And Discrepancies Remain. Health Affairs, 2013, 32, 1109-1115.	5.2	25
17	Despite High Costs, Specialty Drugs May Offer Value For Money Comparable To That Of Traditional Drugs. Health Affairs, 2014, 33, 1751-1760.	5.2	22
18	EXAMINING EVIDENCE IN U.S. PAYER COVERAGE POLICIES FOR MULTI-GENE PANELS AND SEQUENCING TESTS. International Journal of Technology Assessment in Health Care, 2017, 33, 534-540.	0.5	20

#	ARTICLE	IF	CITATIONS
19	Drugs Cleared Through The FDA's Expedited Review Offer Greater Gains Than Drugs Approved By Conventional Process. Health Affairs, 2017, 36, 1408-1415.	5.2	20
20	Coverage for Biosimilars vs Reference Products Among US Commercial Health Plans. JAMA - Journal of the American Medical Association, 2020, 323, 1972.	7.4	20
21	Illustrating Potential Efficiency Gains from Using Cost-Effectiveness Evidence to Reallocate Medicare Expenditures. Value in Health, 2013, 16, 629-638.	0.3	19
22	Medicare's use of cost-effectiveness analysis for prevention (but not for treatment). Health Policy, 2015, 119, 156-163.	3.0	19
23	Insurance coverage for genomic tests. Science, 2018, 360, 278-279.	12.6	18
24	What values do the public want their health care systems to use in evaluating technologies?. European Journal of Health Economics, 2011, 12, 285-288.	2.8	16
25	Variation in US private health plans' coverage of orphan drugs. American Journal of Managed Care, 2019, 25, 508-512.	1.1	14
26	Little Consistency In Evidence Cited By Commercial Plans For Specialty Drug Coverage. Health Affairs, 2019, 38, 1882-1886.	5.2	13
27	An Evidence Review of Low-Value Care Recommendations: Inconsistency and Lack of Economic Evidence Considered. Journal of General Internal Medicine, 2021, 36, 3448-3455.	2.6	12
28	Variation in market access decisions for cell and gene therapies across the United States, Canada, and Europe. Health Policy, 2021, 125, 1550-1556.	3.0	11
29	Patients' access to rare neuromuscular disease therapies varies across US private insurers. Orphanet Journal of Rare Diseases, 2022, 17, 36.	2.7	11
30	Variation In Use And Content Of Prescription Drug Step Therapy Protocols, Within And Across Health Plans. Health Affairs, 2021, 40, 1749-1757.	5.2	10
31	Variation in Private Payer Coverage of Rheumatoid Arthritis Drugs. Journal of Managed Care & Specialty Pharmacy, 2016, 22, 1176-1181.	0.9	9
32	Do Changes in Drug Coverage Policy Point to an Increased Role for Cost-Effectiveness Analysis in the USA?. Pharmacoeconomics, 2014, 32, 729-733.	3.3	8
33	The lag from FDA approval to published cost-utility evidence. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 399-402.	1.4	8
34	The impact of formulary drug exclusion policies on patients and healthcare costs. American Journal of Managed Care, 2016, 22, 524-31.	1.1	7
35	Thirty Years of Media Coverage on High Drug Prices in the United States—A Never-Ending Story or a Time for Change?. Value in Health, 2016, 19, 14-16.	0.3	6
36	Is an Orphan Drug's Cost-Effectiveness Associated with US Health Plan Coverage Restrictiveness?. Pharmacoeconomics, 2022, 40, 225-232.	3.3	6

#	ARTICLE	IF	CITATIONS
37	Medicare's National Coverage Determinations in Diagnostic Radiology. <i>Academic Radiology</i> , 2012, 19, 1060-1065.	2.5	5
38	CHANGING FACE OF MEDICARE'S NATIONAL COVERAGE DETERMINATIONS FOR TECHNOLOGY. <i>International Journal of Technology Assessment in Health Care</i> , 2015, 31, 347-354.	0.5	5
39	What types of real-world evidence studies do U.S. commercial health plans cite in their specialty drug coverage decisions?. <i>Pharmacoepidemiology and Drug Safety</i> , 2020, 29, 1307-1311.	1.9	5
40	Mapping US commercial payers' coverage policies for medical interventions. <i>American Journal of Managed Care</i> , 2016, 22, e323-8.	1.1	5
41	The Decline in Vitamin Research Funding: A Missed Opportunity?. <i>Current Developments in Nutrition</i> , 2017, 1, e000430.	0.3	4
42	A Comparison of Coverage Restrictions for Biopharmaceuticals and Medical Procedures. <i>Value in Health</i> , 2018, 21, 400-406.	0.3	4
43	Discrepancies Between FDA-Required Labeling and Evidence that Payers Cite in Drug Coverage Policies. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2018, 24, 1240-1246.	0.9	4
44	Use of prescriber requirements among US commercial health plans. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2021, 27, 1757-1762.	0.9	3
45	The Role of Decision Models in Health Care Policy. <i>Medical Decision Making</i> , 2016, 36, 666-679.	2.4	2
46	Estimating Population Health Benefits Associated with Specialty and Traditional Drugs in the Year Following Product Approval. <i>Applied Health Economics and Health Policy</i> , 2017, 15, 227-235.	2.1	1
47	Are Medical Devices Cost-Effective?. <i>Applied Health Economics and Health Policy</i> , 2022, 20, 235-241.	2.1	1
48	Potential role of network meta-analysis in value-based insurance design. <i>American Journal of Managed Care</i> , 2014, 20, 641-8.	1.1	1
49	Medicare's Interventions Coverage: The Authors Reply. <i>Health Affairs</i> , 2015, 34, 1066-1066.	5.2	0
50	Limited role of patient input in specialty drug coverage policies. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2021, 27, 1067-1076.	0.9	0
51	Variation in access to hemophilia A treatments in the United States. <i>Journal of Medical Economics</i> , 2021, 24, 1143-1148.	2.1	0
52	Variation in health plan coverage of ESAs for anemia due to chronic kidney disease. <i>Journal of Managed Care &amp; Specialty Pharmacy</i> , 2021, 27, 1221-1229.	0.9	0
53	Docetaxel chemotherapy in metastatic castration-resistant prostate cancer (mCRPC): Cost of care for Medicare and commercially insured men.. <i>Journal of Clinical Oncology</i> , 2016, 34, 262-262.	1.6	0
54	Coverage of Specialty Drugs for Psoriasis and Psoriatic Arthritis by Commercial Insurance Companies. <i>Journal of Psoriasis and Psoriatic Arthritis</i> , 0, , 247553032211018.	0.7	0